Furthermore, gene expression levels may vary with disease stage and therefore, there is need to develop gene therapies that are responsive to this, for example, addressing the declining levels of AADC enzyme or neurotrophic factor in the progressive neurodegeneration of PD. The gene discussed is DDC; the disease is Parkinson disease.